Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
64.7 USD +1.33% Intraday chart for Gilead Sciences, Inc. +0.67% -20.13%
Jun. 06 Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA MT
Jun. 06 Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 82,209 73,031 91,081 107,677 100,942 80,607 - -
Enterprise Value (EV) 1 82,450 103,910 118,530 126,522 118,665 98,773 93,784 88,451
P/E ratio 15.4 x 583 x 14.7 x 23.6 x 18 x 189 x 12.5 x 11.7 x
Yield 3.88% 4.67% 3.91% 3.4% 3.7% 4.79% 5.08% 5.27%
Capitalization / Revenue 3.66 x 2.96 x 3.34 x 3.95 x 3.72 x 2.92 x 2.88 x 2.8 x
EV / Revenue 3.67 x 4.21 x 4.34 x 4.64 x 4.38 x 3.58 x 3.35 x 3.08 x
EV / EBITDA 6.61 x 7.88 x 8.12 x 8.86 x 9.01 x 10.2 x 6.76 x 6.32 x
EV / FCF 9.91 x 13.8 x 11 x 15.2 x 16 x 12.1 x 9.38 x 8.66 x
FCF Yield 10.1% 7.24% 9.12% 6.59% 6.25% 8.24% 10.7% 11.5%
Price to Book 3.65 x 4.04 x 4.32 x 5.05 x 4.48 x 4.08 x 3.57 x 3.14 x
Nbr of stocks (in thousands) 1,265,146 1,253,528 1,254,384 1,254,244 1,246,042 1,245,853 - -
Reference price 2 64.98 58.26 72.61 85.85 81.01 64.70 64.70 64.70
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,449 24,689 27,305 27,281 27,116 27,594 27,986 28,743
EBITDA 1 12,468 13,184 14,598 14,283 13,177 9,666 13,871 13,990
EBIT 1 11,064 11,704 12,548 12,180 10,484 7,255 11,646 12,087
Operating Margin 49.29% 47.41% 45.95% 44.65% 38.66% 26.29% 41.61% 42.05%
Earnings before Tax (EBT) 1 5,160 1,669 8,278 5,814 6,859 1,492 8,168 8,664
Net income 1 5,386 123 6,225 4,592 5,665 386.8 6,305 6,834
Net margin 23.99% 0.5% 22.8% 16.83% 20.89% 1.4% 22.53% 23.78%
EPS 2 4.220 0.1000 4.930 3.640 4.500 0.3420 5.171 5.551
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,136 10,000 10,209
FCF margin 37.06% 30.45% 39.57% 30.59% 27.37% 29.48% 35.73% 35.52%
FCF Conversion (EBITDA) 66.72% 57.02% 74.02% 58.42% 56.32% 84.17% 72.09% 72.97%
FCF Conversion (Net income) 154.46% 6,112.2% 173.57% 181.71% 131% 2,103.48% 158.6% 149.38%
Dividend per Share 2 2.520 2.720 2.840 2.920 3.000 3.101 3.287 3.409
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 7,244 6,590 6,260 7,042 7,389 6,352 6,599 7,051 7,115 6,686 6,703 6,972 7,231 6,484 6,781
EBITDA 1 2,042 4,049 3,195 3,811 3,227 2,883 3,258 3,908 3,427 - 3,365 3,541 3,543 - -
EBIT 1 1,507 3,524 2,670 3,286 2,699 2,243 2,277 3,224 2,739 -1,117 2,680 2,892 2,931 2,587 2,735
Operating Margin 20.8% 53.47% 42.65% 46.66% 36.53% 35.31% 34.51% 45.72% 38.5% -16.71% 39.99% 41.49% 40.53% 39.9% 40.34%
Earnings before Tax (EBT) 1 759 -152 1,503 2,432 2,031 1,300 1,588 2,318 1,653 -4,486 1,792 2,077 2,235 2,370 2,465
Net income 1 382 19 1,144 1,789 1,640 1,010 1,045 2,180 1,429 -4,170 1,378 1,584 1,650 1,662 1,755
Net margin 5.27% 0.29% 18.27% 25.4% 22.2% 15.9% 15.84% 30.92% 20.08% -62.37% 20.56% 22.73% 22.82% 25.63% 25.89%
EPS 2 0.3000 0.0200 0.9100 1.420 1.300 0.8000 0.8300 1.730 1.140 -3.340 1.110 1.275 1.308 1.240 1.322
Dividend per Share 2 0.7100 0.7300 0.7300 0.7300 0.7300 0.7500 0.7500 0.7500 0.7500 0.7700 0.7633 0.7633 0.7633 0.7600 0.7600
Announcement Date 2/1/22 4/28/22 8/2/22 10/27/22 2/2/23 4/27/23 8/3/23 11/7/23 2/6/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 241 30,879 27,449 18,845 17,723 18,167 13,177 7,844
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.0193 x 2.342 x 1.88 x 1.319 x 1.345 x 1.879 x 0.95 x 0.5607 x
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,136 10,000 10,209
ROE (net income / shareholders' equity) 38.3% 43.8% 46.8% 43.3% 38.5% 22% 40.9% 36.5%
ROA (Net income/ Total Assets) 8.6% 0.19% 9.13% 14% 13.5% 4.32% 13% 13%
Assets 1 62,651 65,079 68,180 32,874 41,980 8,962 48,378 52,700
Book Value Per Share 2 17.80 14.40 16.80 17.00 18.10 15.90 18.10 20.60
Cash Flow per Share 2 7.160 6.470 9.020 7.190 6.360 3.010 8.070 8.800
Capex 1 825 650 579 728 585 598 648 657
Capex / Sales 3.67% 2.63% 2.12% 2.67% 2.16% 2.17% 2.31% 2.28%
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7 USD
Average target price
82.7 USD
Spread / Average Target
+27.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-20.13% 80.61B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Financials Gilead Sciences, Inc.